AU2023227368A1 - Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use - Google Patents

Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use Download PDF

Info

Publication number
AU2023227368A1
AU2023227368A1 AU2023227368A AU2023227368A AU2023227368A1 AU 2023227368 A1 AU2023227368 A1 AU 2023227368A1 AU 2023227368 A AU2023227368 A AU 2023227368A AU 2023227368 A AU2023227368 A AU 2023227368A AU 2023227368 A1 AU2023227368 A1 AU 2023227368A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
anlel38b
fatty acid
excipient
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023227368A
Other languages
English (en)
Inventor
Emanuela DEL VESCO
Armin Giese
Johannes LEVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MODAG GmbH
Original Assignee
MODAG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MODAG GmbH filed Critical MODAG GmbH
Publication of AU2023227368A1 publication Critical patent/AU2023227368A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2023227368A 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use Pending AU2023227368A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01
EP22159408.8 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
AU2023227368A1 true AU2023227368A1 (en) 2024-07-18

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023227368A Pending AU2023227368A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Country Status (12)

Country Link
US (1) US20250161273A1 (https=)
EP (1) EP4486340A1 (https=)
JP (1) JP2025508912A (https=)
KR (1) KR20240155237A (https=)
CN (1) CN118715010A (https=)
AU (1) AU2023227368A1 (https=)
CA (1) CA3246018A1 (https=)
CL (1) CL2024002379A1 (https=)
IL (1) IL314952A (https=)
MX (1) MX2024009773A (https=)
PE (1) PE20250781A1 (https=)
WO (1) WO2023166045A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068949A1 (en) 2023-09-26 2025-04-03 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
US20250161273A1 (en) 2025-05-22
CL2024002379A1 (es) 2025-01-24
WO2023166045A1 (en) 2023-09-07
KR20240155237A (ko) 2024-10-28
EP4486340A1 (en) 2025-01-08
MX2024009773A (es) 2024-08-19
IL314952A (en) 2024-10-01
CA3246018A1 (en) 2023-09-07
JP2025508912A (ja) 2025-04-10
CN118715010A (zh) 2024-09-27
PE20250781A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
JP7761371B2 (ja) 対象におけるマイトファジーを改善するための方法
US20250161273A1 (en) Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
KR20140101333A (ko) 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료
US20100099723A1 (en) Bioavailable compositions of metaxalone and processes for producing the same
ES2983643T3 (es) Terapia oral con tridecanoato de testosterona
JP2018538273A (ja) 虚血性脳卒中を処置するための組成物および方法
JP7120691B2 (ja) 非アルコール性脂肪肝炎の予防または治療用の薬学組成物
EP3860594A1 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
KR101967970B1 (ko) 심장혈관 질환의 치료 또는 예방에서 사용하기 위한 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 저해인자 및 상기 저해인자를 포함하는 약학적 조성물
US20150174118A1 (en) Use of laquinimod to delay huntington's disease progression
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
KR20240036651A (ko) 산화성 망막 질환의 진행을 억제하는 방법
CN116323604A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂
EP4717262A1 (en) Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
WO2025068949A1 (en) Emrusolmin for use in treating multiple system atrophy
WO2024210195A1 (ja) 炎症性腸疾患の治療用医薬組成物
WO2026088136A1 (en) Methods of treating a neurodegenerative disease
Qian et al. Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel AChE inhibitor: a single-center, phase I study in healthy young and elderly Chinese subjects
WO2026083443A1 (en) Synergistic nutraceutical composition controlling osteoarthritis through inhibition of its nociceptive and neuropathic pain components
CN118742299A (zh) 监测患者对视网膜氧化性疾病治疗反应的方法
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
RU2575819C2 (ru) Новые составы 14-эпи-аналогов витамина d